Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.

Cubist Pharmaceuticals and Durata Therapeutics both have antibiotics scheduled for regulatory review with the FDA later this month. Which company offers investors the better risk to reward profile?

Mar 20, 2014 at 9:30AM

Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a dramatic drop in share price. Given the bipolar nature of regulatory decisions for biotechs, it's key to understand the risks relative to rewards associated with a company ahead of the event. With that in mind, here is a Foolish comparison of two biotechs, Cubist Pharmaceuticals (NASDAQ:CBST) and Durata Therapeutics (NASDAQ:DRTX), with imminent regulatory reviews for their antibiotics with the U.S. Food and Drug Administration, or FDA.

Cubist Pharmaceuticals and Durata Therapeutics both face the FDA on March 31
In an odd turn of events, both Cubist and Durata will go before Advisory Committees for their respective antibiotics, indicated as potential treatments for gram-positive skin infections, on March 31. Because of the marked increase in serious skin infections stemming from antibiotic resistant bacteria such as Staphylococcus aureus (MRSA), the Centers for Disease Control (CDC) has stated that there is an urgent need to develop new antibiotics to fill this unmet medical need. According to the CDC, 2 million Americans per year are infected with antibiotic resistant bacteria, resulting in approximately 23,000 fatalities. And the problem is only growing worse.

Cubist offers tedizolid phosphate
Cubist's antibiotic candidate is tedizolid phosphate, which was acquired from Trius Therapeutics in 2013 and will be marketed by Bayer AG outside of the U.S. Tedizolid met both its primary and secondary endpoints in two late-stage trials and is presently under review as a treatment for acute bacterial skin and skin structure infections (ABSSSI). Tedizolid will also enter mid-stage trials this year as potential treatment for hospital-acquired/ventilator-associated bacterial pneumonia. Based on Cubist's prior successes with the FDA, tedizolid's strong late-stage trial results, and the clear need for new antibiotics, I think tedizolid will receive a positive vote come March 31. A final decision for tedizolid is set for June 20, which is the drug's scheduled Prescription Drug User Fee Act, or PDUFA, action date 

Durata offers dalbavancin
Durata's candidate is the storied dalbavancin. Durata was launched in 2009 specifically to raise money to acquire the broad spectrum antibiotic from Pfizer (NYSE:PFE). Pfizer acquired the drug in a whopping $1.9 billion deal for Vicuron Pharmaceuticals in 2005, but was unable to monetize dalbavancin for reasons that remain somewhat fuzzy to this day.

After acquiring the drug from Pfizer, Durata initiated the requisite clinical trials necessary for a regulatory filing in the U.S. and Europe. In 2012, the company reported that dalbavancin met both its primary and secondary endpoints in multiple late-stage trials and subsequently filed for regulatory approval. So, despite a meandering clinical and regulatory history, my view is that dalbavancin will also likely be approved as a treatment for ABSSSI before or on May 26, the drug's scheduled PDUFA date. 

Foolish comparison
While this comparison seems unfair given the dramatic difference in market cap between the two companies, I believe you can consider which company offers the most potential upside for the least amount of risk. Viewed this way, I think the bigger biotech, Cubist, is the clear winner. Even though both stand a good chance of gaining approval for their respective antibiotics, my opinion is that Durata will have a much tougher go on the commercialization front. And will likely have to resort to significant dilutive financing to help raise the funds necessary to create a commercial infrastructure. Cubist has the marked advantage of already being a market leader in the antibiotic field with its blockbuster Cubicin, and thus having significant cash flow that can be used to help launch new drugs. All told, Durata simply can't offer investors this margin of safety. 

6 more hyper-growth stocks
Cubist and Durata aren't the only fast-growing stocks out there, although finding them can be difficult. In fact, they said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


George Budwell has no position in any stocks mentioned. The Motley Fool recommends Cubist Pharmaceuticals. The Motley Fool owns shares of Cubist Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information